Siavash Nael, MD
Behavioral Neurology & Neuropsychiatry · Oklahoma City, OKNPI 1902809353
Payments from drug & device makers
Across 171 payments — averaging $453.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$47K
- Livanova USA, Inc.$17K
- AbbVie$11K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$360
- Vanda Pharmaceuticals Inc.$205
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$5,82059%
- Travel & lodging$4715%
- Food & beverage$3,58636%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $46,912 |
| Livanova USA, Inc. | 5 | $17,249 |
| AbbVie(2 entities) | 29 | $10,579 |
| Johnson & Johnson | 37 | $1,062 |
| Otsuka America Pharmaceutical, Inc. | 20 | $360 |
| Vanda Pharmaceuticals Inc. | 11 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $144 |
| Jazz Pharmaceuticals Inc. | 5 | $115 |
| Pacira Therapeutics, Inc. | 1 | $111 |
| Amgen | 5 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Brainsway USA Inc | 1 | $54 |
| Shionogi Inc | 3 | $53 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Biodelivery Sciences International, Inc. | 3 | $41 |
| Medtronic(2 entities) | 2 | $39 |
| Sentynl Therapeutics, Inc. | 3 | $37 |
| Shire North American Group Inc | 2 | $34 |
| Lundbeck LLC | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $29 |
| Harmony Biosciences LLC | 1 | $27 |
| Bausch Health US, LLC | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Novartis | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Indivior Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$6,337
- SPRAVATO$423
- VRAYLAR$241
- Zilretta$111
- INVEGA SUSTENNA$102
- INVEGA TRINZA$102
How this compares
Too few behavioral neurology & neuropsychiatry providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 31 | $1,642 |
| Duloxetine Hcl | 85 | $1,146 |
| Fluphenazine Decanoate | 11 | $1,018 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 50 | $976 |
| Hydroxyzine Hcl | 34 | $804 |
| Doxepin Hcl | 44 | $732 |
| Aripiprazole | 39 | $681 |
| Olanzapine | 52 | $642 |
| Quetiapine Fumarate | 48 | $621 |
| Risperidone | 45 | $512 |
| Bupropion XlBupropion Hcl | 37 | $493 |
| Bupropion Hcl SrBupropion Hcl | 56 | $477 |
| Lamotrigine | 32 | $427 |
| Mirtazapine | 39 | $423 |
| Paroxetine CrParoxetine Hcl | 12 | $394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $29 | $64252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in Oklahoma City
- Jeffrey CraigOklahoma City$313
- Ruth SeamanTulsa$66
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.